Louise Jarrett, RGN, BA; Siobhan M. Leary, MRCP; Bernadette
Porter, RGN; Davina Richardson, BSc, MSc, CSP;
Tiziana Rosso, MD; Michael Powell, FRCS; and Alan J. Thompson, MD, FRCP
Louise Jarrett is a Spasticity Management Clinical Nurse
Specialist, National Hospital for Neurology and Neurosurgery,
University College London Hospitals, Queen Square, London,
United Kingdom. Siobhan M. Leary is a Research Fellow, Institute
of Neurology, Queen Square, London, United Kingdom. Bernadette
Porter is a Multiple Sclerosis Clinical Nurse Specialist,
National Hospital for Neurology and Neurosurgery, University
College London Hospitals, Queen Square, London, United Kingdom.
Davina Richardson is a Clinical Physiotherapy Specialist,
National Hospital for Neurology and Neurosurgery, University
College London Hospitals, Queen Square, London, United Kingdom.
Tiziana Rosso was a Visiting Research Fellow, Institute of
Neurology, Queen Square, London, United Kingdom, at the time
this paper was prepared. Dr. Rosso is now at Servizio di
Neurologia ad indirizzo Riabilitativo, Dipartimento di Scienze
Neurologiche e della Visione, Universita’ degli Studi di
Verona, Italy. Michael Powell is a Consultant Neurosurgeon,
National Hospital for Neurology and Neurosurgery, University
College London Hospitals, Queen Square, London, United Kingdom.
Alan J. Thompson is a Professor of Clinical Neurology and
Neurorehabilitation, Institute of Neurology, Queen Square,
London, United Kingdom.
|
Abstract
The effectiveness of
intrathecal baclofen therapy (ITB) in the management of severe
spasticity in people with multiple sclerosis (MS) was reviewed
retrospectively. The multidisciplinary team reviewed the
medical, therapy, and nursing notes of 19 people with MS who
were treated with ITB. The audited information included surgical
procedures, postoperative complications, medical side effects,
dose requirements, and multidisciplinary input.
Seventeen people were
included in the audit. A total of 23 problems and 34 functional
goals as objects for ITB treatment were recorded. Eighty-seven
percent of the patients had sustained improvement in at least
one problem, and 79% in at least one goal. Only two patients had
no sustained improvement in any problem or goal. These results
suggest that ITB can be an effective intervention in people with
severe spasticity in MS. However, this approach requires careful
patient selection, a dynamic goal-oriented approach, expert
implantation, and ongoing evaluation of individual responses to
treatment over time.
Suggested citation: Managing Spasticity in People With
Multiple Sclerosis: A Goal-Oriented Approach to Intrathecal
Baclofen Therapy. Jarrett, L et al. Int J MS Care [Serial
on-line]. December 2001;3(4).
Intrathecal baclofen (ITB) is an effective treatment option
in the management of severe spasticity of either cerebral1,2
or spinal origin,3,4 and benefit is sustained over a
period of time.5,6 The use of ITB, however, is not
without risk. To assure that complications are minimized while
therapeutic benefit is maximized, a coordinated approach by an
experienced team including a neurologist, a neurosurgeon,
physiotherapists, nurses, and occupational therapists is
advisable.7,8
Baclofen (Lioresal®) acts by binding to gamma-aminobutyric
acid (GABA) receptors. It has a presynaptic inhibitory effect on
the release of excitatory neurotransmitters.9
Postsynaptically it decreases the firing of motor neurons.10
This results in inhibition of monosynaptic and polysynaptic
spinal reflexes,11 with associated reductions in
spasm, clonus, and pain. Delivering baclofen intrathecally
accentuates its antispasticity effect while minimizing the
troublesome systemic side effects associated with oral intake.
Baclofen can be administered intrathecally via a
subcutaneously implanted electronic pump with a reservoir and a
catheter (SynchroMed Infusion System, Medtronic Ltd.) with the
tip placed at L2/L3 or higher. This system is externally
programmed using a computer and telemetry, allowing different
dose regimes to be delivered. A 24-hour dose can have up to 10
steps, each prescribing the dose, rate, and duration, allowing
the delivery of complex regimes. The two pumps currently
available are of identical diameter (70.4 mm) and battery life
(five to seven years) but differ in reservoir size (10 mL and 18
mL). It should be noted, however, that our recommendations are
based on our experience with previous models, which had a
battery life of three to five years.
This paper is a retrospective audit of one unit’s
experience of using ITB during a five-year period. It provides
evidence of efficacy as recorded in clinical practice,
demonstrating the need for a comprehensive, multidisciplinary
management strategy, incorporating clearly defined goals and
responsive to changing clinical needs.
Methods
The medical, therapy, and nursing notes were retrospectively
reviewed for 19 people with MS who had ITB pumps implanted for
management of severe spasticity. The review panel consisted of
two neurologists, two nurse specialists, and one physiotherapist
involved in the subjects’ care. The problems and goals agreed
upon before treatment were identified from the notes for each
individual. Problems related to impairment or symptoms, such as
spasms. Goals—which had been set from the patient perspective
and had to be realistic and potentially achievable—concerned
improvement of function or comfort, such as improved sitting
posture. To evaluate treatment outcome, the sustained
improvement in the problems and the level of achievement of the
goals over time were identified and graded by the
multidisciplinary team. Achievement had to last for at least
three months. The following grading system was used: nil (not
improved or achieved), mild, moderate, or marked improvement or
achievement. Transient response was also recorded.
Surgical procedures, postoperative complications, medical
side effects, dose requirements, and multidisciplinary
involvement were noted. Outcome measures used to assess
spasticity were documented, but these varied during the five
years, making comparison difficult. Therefore, they were not
included in the data.
Surgical
Technique
Certain aspects of the surgical technique were modified to
make the procedure more effective. These include where the Touhy
needle is inserted and the position of both the lumbar and
abdominal incisions. Current practice is summarized as follows:
- The body of the patient is flexed and placed in the
lateral position with the upper arm elevated on an arm
support, thus exposing the abdomen for the pump placement,
but also ensuring the true upright position. This eases the
insertion of the lumbar catheter.
- A 4- to 5-cm horizontal incision over the area of lumbar
vertebrae 3 and 4 has proved sufficient. Therefore, a
longitudinal incision has been abandoned, because it makes
it more difficult to secure the catheter.
- The Touhy needle (SIMS Portex Ltd, Kent, UK) is inserted
off the midline to pass through the muscle of erector spinae
rather than through the interspinous ligament. This reduces
cerebrospinal fluid (CSF) from flowing back, perhaps because
the muscle makes a more permanent seal.
- The needle is passed directly through to the CSF rather
than using the standard air injection method. Once the dura
is penetrated and clear CSF flow is demonstrated, the stylet
of the needle is replaced to minimize leakage.
- The catheter is inserted with the guidewire cephalad to
about 10 cm or between the third and fourth marks. If it
will not pass initially, the needle is withdrawn a few
millimeters, which usually unblocks the tip opening,
although CSF flow must be reconfirmed. First the needle,
then the guidewire, are removed, the latter by holding the
catheter at the entry point to the spine and pulling the
guidewire at the loose end. A curved channel is the best way
to anchor the catheter as this takes strain off the entry
point and directs the catheter toward the pump.
- The abdominal pocket is fashioned at the same time by a
second surgeon, either in the left or right abdominal
quadrant. An oblique 10- to 12-cm incision is sufficient.
This prevents producing a relatively avascular flap and
avoids an incision line that lies over the pump itself. Both
of these modifications can aid in reducing infection. The
pocket is then fashioned medial to this incision. A dummy
pump is useful for determining the correct size.
- While the first surgeon is still at work creating the
anchorage for the catheter, the pocket can be packed with a
povidone-iodine–soaked swab both to minimize oozing and
reduce infection.
- Any tunneling device can be used to connect the two
incisions. Once the pump is prepared, it can be connected to
the suitably shortened catheter, leaving enough slack to
allow some movement from subsequent spasms. The pump is
inserted with the catheter lying behind it, and the
incisions are closed.
Results
Nineteen sets of notes were reviewed: 17 were included in the
audit, one patient’s care had been transferred locally, and
one patient had died (unrelated to ITB therapy). The review
group consisted of six men and 11 women with a mean age of 49
years (range, 38 to 67 years). The mean duration of therapy was
43 months (range, four to 79 months). Twenty-seven pumps (25
electronic, two manual) were implanted; eight were
replacements—four due to expiration of batteries and three
were due to malfunction (one electronic and two manual). One
pump was replaced and relocated onto the other side of the
abdomen because of an infection at the pump site. Five catheters
were replaced, and one catheter was resutured.
Problems
and Goals
Twenty-three problems were identified—10 related to painful
spasms, eight to non-painful spasms, four to spasticity, and one
to pain not associated with spasticity. Thirty-four treatment
goals relating to spasticity management were set (Table 1). The
most common goals were improvement of transfers and pain relief.
Table
1. Type and Number of Goals Relating to Spasticity
Management. |
Goals
identified |
No. |
Improve
transfers |
9 |
Relieve
pain |
8 |
Improve
sitting |
6 |
Use
standing equipment |
4 |
Improve
perineal access |
3 |
Improve
sleep |
2 |
Reduce systemic toxicity |
1 |
Improve
scoliosis |
1 |
Total |
34 |
Sustained improvement to varying degrees was seen in 87% of
the problems, with the largest number of patients showing
moderate improvement (44%, n = 10) (Figure 1). Although three
patients showed no sustained improvement, all three problems
demonstrated a transient improvement: moderate in two patients,
and marked improvement in the third patient.
|
Figure
1: Percentage of problems with sustained improvement
following ITB therapy. |
The patients attained sustained goal achievement in 79% of
the goals they had set (Figure 2). Of the 21% of goals for which
achievement was not sustained, 15% (n = 5) showed transient
achievement: mild, 6% (n = 2); moderate, 3% (n = 1); and marked,
6% (n = 2).
Fifteen patients (88%) had sustained improvement in at least
one problem and one goal. Only two patients (12%) had no
sustained benefit for any problem or goal.
|
Figure
2: Percentage of goal achievement following ITB
therapy. |
Postoperative
and Follow-up Complications
Table 2 summarizes the postoperative complications and
medical side effects experienced by this group. Transient,
low-grade fever was the most common postoperative complication;
it tended to resolve in 24 to 48 hours. The main medical side
effect is excessive weakness, predominantly truncal. This
required frequent dose titration, balancing reduction in tone
against exposing underlying weakness to avoid worsening upper
body function and wheelchair posture.
Table
2. Type and Number of Postoperative Complications
and Medical Side Effects. |
Postoperative
complications |
No. |
Transient
fever |
11 |
Excessive
weakness |
5 |
Headache |
4 |
Drowsiness |
3 |
Respiratory
depression |
3 |
Lumbar
wound complications |
2 |
Abdominal wound complications |
2 |
Neck
stiffness and pain |
2 |
Other |
8 |
Total |
40 |
Five patients reported weight gain following use of ITB. This
has the potential of causing difficulties refilling the
reservoir, even when using a template, and on one occasion an
x-ray was required to facilitate refilling.
Four radiopaque studies have been carried out to assess the
patency of systems demonstrating suboptimal performance. One
study was complicated by a baclofen overdose. The person was
ventilated overnight until the effects of the baclofen had worn
off and subsequently made a complete recovery.
Dose
Adjustments
In response to clinical need, from 0 to 10 dose adjustments
were required per patient per year. Currently, 12 people are
being administered a continuous infusion of a specific dose
throughout 24 hours. Five people have a repetitive sequence of
between two and four steps. The dose during 24 hours ranges from
3 µg to 625 µg, with a mean of 283.2 µg. The length of time
needed to reach an optimal therapeutic dose is extremely
variable and is an ongoing process based on the clinical status
of the person. Follow-up of individual patients ranged from one
to six months, which was dependent upon how well the spasticity/pain
was being controlled and the dose and concentration of drug
used. In addition, one patient experienced temperature-related
changes in tone: during the hot summer months less baclofen was
required for spasm control without weakness. This variation is
now managed by twice-yearly dose adjustments. Four patients
described a "wearing off effect" within one month
before requiring a pump refill, which resolved 24 hours after
having their pump refilled.
Multidisciplinary
Input
Following implantation, 12 patients had their wheelchair
posture and seating reassessed and revised. The adjustments
improved posture and comfort when sitting. Twelve patients made
gains with targeted therapy input as an outpatient, and seven
benefited from a focused inpatient rehabilitation admission.
Following neurophysiotherapy, four patients used standing
equipment who previously had been unable to use it.
Discussion
Intrathecal baclofen is not without
complications, but in carefully selected patients it can be an
effective treatment for spasticity in MS. To maximize efficacy,
it should be only one part of a comprehensive multidisciplinary
management strategy that incorporates clearly defined goals that
are responsive to changing needs. The key points to consider
when using ITB include providing an infrastructure to ensure a
coordinated multidisciplinary service, identifying problems and
goals to guide patient management, and being alert to any
practical difficulties possibly unique to this treatment. The
audit demonstrated that a successful ITB service requires
collaboration between the patient and a number of health care
professionals, including neurologists, neurosurgeons,
therapists, and nurses at all four stages of the treatment
process: assessment, trial, implant, and ongoing follow-up
(Table 3).
Assessment
Skilled multidisciplinary assessment allows accurate
selection of individuals who may benefit from ITB therapy and
the identification of achievable goals. Education of patients at
each stage is key to informing them about the process and, most
important, being clear about what ITB can and cannot achieve.
The results show that identifying problems and goals amenable to
treatment provides a useful focus for the patient and the
multidisciplinary team to assess effectiveness.
Trial
The trial stage is important, as it allows the patient to
experience the effect of ITB, and it indicates whether a person
will respond to the therapy. However, it does not provide an
indication of the appropriate therapeutic dose. This is best
achieved by multidisciplinary assessment of response and careful
post-implant dose titration.
Implant
A consultant neurosurgeon implanted all the pumps; this led
over time to the modification of the surgical technique to
optimize the functioning of the implanted system. Although it is
usually a straightforward neurosurgical procedure, pump
implantation is intricate. Patients with spasticity can be thin
and often have unusual fixed deformities, which can lead to
neurosurgical complications. These include leaking back of
cerebrospinal fluid around the catheter track, damage to or
dislodging of the catheter, and infection and breakdown of the
abdominal wound. For these reasons, it is suggested that the
procedure be carried out by an experienced surgeon. This differs
from other common neurosurgical procedures, such as the
implantation of lumboperitoneal shunts, for which senior
trainees have the lowest complication rate.12
Postsurgical complications and catheter problems have been
previously documented5, 13-16 and were evident in
this review. A one-piece new catheter design (rather than a
two-piece design) has recently been introduced to try to
minimize catheter revisions. It is easier to implant and reduces
the need for dye studies to check the patency of systems. Such
studies require the pump to be stopped, emptied, and filled with
sterile saline. Because such a procedure carries the risk of
drug overdose, an inpatient admission is required, adding to the
cost of running the service.
Careful consideration needs to be given regarding the size of
pump to be implanted. A smaller pump may be preferred in a
patient with a low body weight or little muscle bulk, but the
relatively small advantages in the dimensions of the pump need
to be outweighed against losing 8 mL of reservoir volume, which
can mean frequent refilling of the pump. One patient in our
review with a 10-mL reservoir required refilling on a monthly
cycle. This cannot be counteracted by using a higher
concentration of baclofen, as it is not currently available in a
stable form above 3,000 µg/mL.
Ongoing
Management
Skilled assessment and treatment by a neurophysiotherapist
and occupational therapist is pivotal to spasticity management
and continues to be so when using ITB. Postural tone and
spasticity can be affected by an individual’s position in
lying, standing, and sitting. Selecting appropriate physical
treatment strategies will help to manage tone and to minimize
secondary soft tissue changes. Standing (with or without
supportive devices) with good limb and body alignment can help
to improve tone.17 Symmetrical posture and alignment
in a wheelchair prevents joints and muscles from becoming fixed
in abnormal and often painful positions and can promote
functional use of the upper limbs.
Adequate time and personnel to carry out safe, effective
follow-up need to be incorporated into delivering an ITB
service, without which the benefits of ITB may not be realized.
In this audit, monthly refill clinics were run by a neurologist
and a nurse practitioner, during which a spasticity management
review was completed, the pump refilled, dose adjustments made,
and any further education with regard to tone management was
discussed. If required, liaison with members of their primary
health care team or outpatient therapists helped to maximize an
individual’s spasticity management.
Patients who experienced a "wearing off effect" may
be sensitive to changes in the stability of baclofen. To prevent
this in practice, the pumps of these patients are refilled
earlier than indicated by their low reservoir alarm date.
A backup system to respond to emergencies out of hours also
needs to be established. One method is to designate a ward where
the nursing staff are trained in certain aspects of ITB and have
access to detailed protocols. In the event of a complication out
of hours they can offer support or put the patient or any member
of their primary health care team in contact with a neurologist.
A further advantage of this system is that the nurse
practitioner (under the supervision of a neurologist) is able to
forewarn the ward nurses and doctors of specific patients who
are experiencing problems and may require advice or admission
outside of normal office hours. This has facilitated smoother
admissions into the hospital.
Conclusion
This review of data on 17 patients with MS who use ITB
demonstrates that it can be an effective treatment for improving
problems relating to spasticity and for achieving specific
treatment goals. The service requires a multidisciplinary,
coordinated approach during the assessment, selection,
implantation phase, and long-term follow-up. A further study to
examine the cost implications of this treatment would be timely.
References
- Albright AL, Cervi A, Singletary J. Intrathecal baclofen
for spasticity in cerebral palsy. JAMA.
1991;265:1418-1422.
- Meythaler JM, McCary A, Hadley MN. Prospective assessment
of continuous intrathecal infusion of baclofen for
spasticity caused by acquired brain injury: a preliminary
report. J Neurosurg. 1997;87:415-419.
- Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen
for severe spinal spasticity. N Engl J Med.
1989;320:1517-1521.
- Loubser PG, Narayan RK, Sandin KJ, et al. Continuous
infusion of intrathecal baclofen: long-term effects on
spasticity in spinal cord injury. Paraplegia.
1991;29:48-64.
- Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen
for intractable spasticity of spinal origin: results of a
long-term multicenter study. J Neurosurg.
1993;78:226-232.
- Ochs G, Struppler A, Meyerson BA, et al. Intrathecal
baclofen for long-term treatment of spasticity: a multi-centre
study. J Neurol Neurosurg Psychiatry.
1989;52:933-939.
- Becker WJ, Harris CJ, Long ML, et al. Long-term
intrathecal baclofen therapy in patients with intractable
spasticity. Can J Neurol Sci. 1995;22:208-217.
- Gardner B, Jamous A, Teddy P, et al. Intrathecal baclofen—a
multicentre clinical comparison of the Medtronics
Programmable, Cordis Secor and Constant Infusion Infusaid
drug delivery systems. Paraplegia. 1995;33:551-554.
- Fox S, Krnjevic K, Morris ME, et al. Action of baclofen on
mammalian synaptic transmission. Neuroscience.
1978;3:495-515.
- Davies J. Selective depression of synaptic excitation in
cat spinal neurones by baclofen: an iontophoretic study. Br
J Pharmacol. 1981;72:373-384.
- Davidoff RA, Sears ES. The effects of Lioresal on synaptic
activity in the isolated spinal cord. Neurology.
1974;24:957-963.
- Renier D, Lacombe J, Pierre-Kahn A, et al. Factors causing
acute shunt infection. Computer analysis of 1174 operations.
J Neurosurg. 1984;61:1072-1078.
- Porter B. A review of intrathecal baclofen in the
management of spasticity. Br J Nurs.
1997;6:253-260,262.
- McLean BN. Intrathecal baclofen in severe spasticity. Br
J Hosp Med. 1993;49: 262-267.
- Penn RD. Intrathecal baclofen for spasticity of spinal
origin: seven years of experience. J Neurosurg.
1992;77:236-240.
- Teddy P, Jamous A, Gardner B, et al. Complications of
intrathecal baclofen delivery. Br J Neurosurg.
1992;6:115-118.
- Edwards S. Physiotherapy management of established
spasticity. In: Sheean G, Barnes MP, eds. Spasticity
Rehabilitation. London, Great Britain: Churchill
Communications Europe Ltd; 1998:71-89.
information provided by: http://www.mscare.com/ |